Otlertuzumab - Aptevo Therapeutics

Drug Profile

Otlertuzumab - Aptevo Therapeutics

Alternative Names: TRU-016

Latest Information Update: 24 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Aptevo Therapeutics
  • Class Antineoplastics; Monoclonal antibodies; Small molecules
  • Mechanism of Action Apoptosis stimulants; CD37 protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Peripheral T-cell lymphoma
  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 24 Jan 2018 Otlertuzumab is still in phase I trials for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy) in USA (IV) (NCT01644253) (Aptevo website, January 2018)
  • 23 Jan 2018 Otlertuzumab is at phase II development stage for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in Austria, Germany, Poland, Spain and USA (IV) (Aptevo Therapeutics pipeline, January 2018)
  • 08 Jan 2018 Phase-II clinical trials in Peripheral T-cell lymphoma (Second-line therapy or greater, Combination therapy) (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top